USA-based Juno Therapeutics (Nasdaq: JUNO) has joined forces with China’s WuXi AppTec, a leading open-access R&D capability and technology platform company, to establish a new, equally-owned, company in China.
To be called JW Biotechnology (Shanghai) Co, the new firm’s mission is to build China's leading cell therapy company by leveraging Juno's world-class chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies together with WuXi AppTec's R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solid-organ cancers.
James Li, formerly a Kleiner Perkins partner and general manager of Amgen China, and a JW Biotechnology co-founder, has been appointed chief executive of the joint venture.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze